RxDoctor Payments Data

Pamela Santone, DO

Family Medicine · Grand Prairie, TXNPI 1528033941

Payments from drug & device makers

$15,615in general payments, 2019–2025

Across 783 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$1K
  • GSK$808
  • plus $7K from 46 others

What the payments were for

  • Consulting fees$1,70011%
  • Speaking & faculty fees$2502%
  • Food & beverage$13,55987%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,615 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$90,899
Medicare patients
161
Services billed
1,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$91,871
MounjaroTirzepatide42$73,688
JardianceEmpagliflozin45$55,009
EliquisApixaban41$35,755
JanuviaSitagliptin Phosphate29$27,877
XareltoRivaroxaban35$27,730
Synjardy XrEmpagliflozin/Metformin Hcl17$18,466
FarxigaDapagliflozin Propanediol15$17,109
TrulicityDulaglutide16$15,076
LinzessLinaclotide11$10,977
Ibandronate Sodium102$3,866
Levothyroxine Sodium254$2,988
Varenicline Tartrate13$2,953
Olmesartan Medoxomil184$2,855
Albuterol Sulfate HfaAlbuterol Sulfate84$2,592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,822$91,87157 claims
Lilly USA, LLCMounjaro, Trulicity$1,050$88,76558 claims
Boehringer IngelheimJardiance, Synjardy Xr$614$73,47562 claims
PfizerEliquis$750$35,75541 claims
MerckJanuvia$180$27,87729 claims
Johnson & JohnsonXarelto$75$27,73035 claims
AstraZenecaFarxiga$1,668$17,10915 claims
AbbVieLinzess, Synthroid$1,684$13,42943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Grand Prairie

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →